Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Toxicology. 2021 Nov 2;464:153016. doi: 10.1016/j.tox.2021.153016

Fig. 1. The effect of CBD on TLR 1 activated monocytes.

Fig. 1.

Monocytes were either unstimulated (U.S.), activated with TLR 1 agonist, PAM3CSK4, at 100 ng/mL (activation only control), or activated with PAM3CSK4 in combination with vehicle (0.03% ethanol; Vh), then cultured for 22 hours (A, C, E, G, I, and L). These graphs present the unnormalized concentration of each cytokine and chemokine. Figures were statistically analyzed by repeated measures one-way ANOVA with Sidak’s post-hoc test. Asterisks denote statistically significant differences compared to U.S. (*p < 0.05, ***p < 0.001, ****p < 0.0001) as determined by repeated measures one-way ANOVA with Sidak’s post-hoc test. Pound symbols denote statistically significant differences between activated and Vh treated cells (#p < 0.05). Monocytes were activated with PAM3CSK4 and treated with Vh or CBD (0.5, 1, 5, or 10 μM), then cultured for 22 hours (B, D, F, H, J, and M). After quantification of cytokine and chemokine, values were normalized to the PAM3CSK4 activation only control and presented as a percentage. Asterisks denote statistically significant differences from the Vh control in each graph (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001) as determined by repeated measures one-way ANOVA with Dunnett’s post-hoc test. All graphs are means S.E.M. (A-M) (n = 6).